ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) Total Score.
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) Total Score.
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
-
Clinical Site, Little Rock, Arkansas, United States, 72211
Clinical Site, Bellflower, California, United States, 90706
Clinical Site, Culver City, California, United States, 90230
Clinical Site, Garden Grove, California, United States, 92845
Clinical Site, Lemon Grove, California, United States, 91945
Clinical Site, Los Angeles, California, United States, 90015
Clinical Site, Montclair, California, United States, 91763
Clinical Site, Orange, California, United States, 92868
Clinical Site, Riverside, California, United States, 92506
Clinical Site, San Diego, California, United States, 92123
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 64 Years
ALL
No
MapLight Therapeutics,
MapLight Therapeutics, STUDY_DIRECTOR, MapLight Therapeutics
2027-01